Algert Global LLC Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA)

Algert Global LLC acquired a new position in Sana Biotechnology, Inc. (NASDAQ:SANA) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 13,286 shares of the company’s stock, valued at approximately $73,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in Sana Biotechnology in the second quarter worth approximately $100,000. Hartline Investment Corp acquired a new position in shares of Sana Biotechnology during the 1st quarter valued at $136,000. Dark Forest Capital Management LP boosted its stake in Sana Biotechnology by 112.0% during the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after acquiring an additional 14,430 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Sana Biotechnology by 20.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after purchasing an additional 5,090 shares during the period. Finally, Arizona State Retirement System increased its stake in Sana Biotechnology by 36.7% in the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after purchasing an additional 9,940 shares in the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SANA has been the topic of a number of research analyst reports. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They set a “buy” rating and a $16.00 price objective on the stock. Citigroup raised their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright lowered their target price on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, August 9th.

Sana Biotechnology Stock Performance

Shares of SANA opened at $3.99 on Friday. The firm has a market capitalization of $883.80 million, a P/E ratio of -2.61 and a beta of 1.42. Sana Biotechnology, Inc. has a 52 week low of $2.74 and a 52 week high of $12.00. The stock has a 50 day moving average price of $4.81 and a two-hundred day moving average price of $6.53.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). On average, equities analysts forecast that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current year.

Insider Activity

In related news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 31.10% of the stock is currently owned by corporate insiders.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.